Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mundipharma Laboratories GmbH

Division of Mundipharma International Corp. Ltd.
www.mundipharma.net

Latest From Mundipharma Laboratories GmbH

PIPELINE WATCH: A Strong Analgesic Meets Primary Endpoint, But An RNAi Therapeutic Disappoints

Pipeline Watch has been updated to bring greater depth and detail to a product’s progress through the R&D pipeline, and is now a snapshot of late-stage, Phase II and III clinical trial events for drugs being evaluated by the pharma and biotech industries that is now available to view.

Pipeline Watch Approvals

Deals Shaping The Medical Industry, February 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014-January 2015.

BioPharmaceutical Medical Device

Deal Watch: Roche/Foundation Medicine Highlights Hyper Deal-Making During J.P. Morgan

Biogen will purchase GSK spinout Convergence to bolster its pain portfolio, while Tekmira and OnCore are merging to create a new company focused on hepatitis B. Two J&J units struck deals during the week in Alzheimer’s and gastrointestinal indications, as Lilly teamed up with Merck and Bristol for combo trials to keep its drugs relevant in the PD-1 world.

BioPharmaceutical Deals

Infinity Gets More Than A Cash Boost With AbbVie Tie-Up

In a deal worth more than $800 million, AbbVie injects a vote of confidence into Infinity’s late-stage PI3K inhibitor program, but leaves the biotech the freedom to conduct other partnerships.

BioPharmaceutical Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Mundipharma AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Mundipharma International Corp. Ltd.
  • Senior Management
  • Antony Mattessich, Mng. Dir.
  • Contact Info
  • Mundipharma Laboratories GmbH
    Phone: (41) 61 205 11 12
    St Alban-Rheinweg 74
    Basel, CH-4020
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register